NCT03464968View on ClinicalTrials.gov

mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 29, 2015

Primary Completion Date

February 10, 2020

Study Completion Date

July 25, 2020

Conditions
Biliary Cancer Metastatic
Interventions
DRUG

Oxaliplatin,5FU, leucovorin

mFOLFOX

DRUG

irinotecan,5FU, leucovorin

mFOLFIRI

Trial Locations (1)

13620

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors
lead

Seoul National University Bundang Hospital

OTHER

NCT03464968 - mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line | Biotech Hunter | Biotech Hunter